Alexion Pharmaceuticals (ALXN) - FREE Research Report

Squinto Stephen P who is EVP, Chief Global Ops. Officer at Alexion Pharmaceuticals sold 304 shares at $112.54 on Sept. 26, 2013. Following this transaction, the EVP, Chief Global Ops. Officer owned 105,186 shares meaning that the stake was reduced by 0.29% with the 304 share transaction.

The shares most recently traded at $115.51, up $2.97, or 2.57% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,737
  • 12-Week # shares sold: 398,838
  • 24-Week # shares sold: 512,401

The average volume for Alexion Pharmaceuticals has been 1.4 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $22.2 billion and is part of the health care sector and drugs industry. Shares are up 21.18% year to date as of the close of trading on Thursday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company has a P/E ratio of 64.5. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Sapient (SAPE) Showing Signs Of Being Strong And Under The Radar

Don't Miss Today's Strong And Under The Radar Stock: Sapient (SAPE)

Watch Out: Barbarians At The Gate For Sapient (SAPE)

Sapient (SAPE) Stock Closed Lower Today After Fiduciary Duty Investigation Launched

Today's Unusual Social Activity Stock: Sapient (SAPE)